Free Trial

NextCure (NXTC) Stock Price, News & Analysis

NextCure logo
$5.03 -0.10 (-1.95%)
Closing price 08/29/2025 03:59 PM Eastern
Extended Trading
$5.15 +0.12 (+2.39%)
As of 08/29/2025 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NextCure Stock (NASDAQ:NXTC)

Key Stats

Today's Range
$5.02
$5.18
50-Day Range
$4.74
$6.17
52-Week Range
$2.69
$19.20
Volume
5,856 shs
Average Volume
21,522 shs
Market Capitalization
$13.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50
Consensus Rating
Moderate Buy

Company Overview

NextCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
88th Percentile Overall Score

NXTC MarketRank™: 

NextCure scored higher than 88% of companies evaluated by MarketBeat, and ranked 126th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NextCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    NextCure has only been the subject of 3 research reports in the past 90 days.

  • Read more about NextCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NextCure has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NextCure's valuation and earnings.
  • Percentage of Shares Shorted

    4.30% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently increased by 216.91%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NextCure does not currently pay a dividend.

  • Dividend Growth

    NextCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.30% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently increased by 216.91%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NextCure has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NextCure this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for NXTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NextCure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NextCure's insider trading history.
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NXTC Stock News Headlines

NextCure (NXTC) Q2 Loss Widens 71%
Trump’s national nightmare is here
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More Headlines

NXTC Stock Analysis - Frequently Asked Questions

NextCure's stock was trading at $9.2520 on January 1st, 2025. Since then, NXTC stock has decreased by 45.6% and is now trading at $5.03.

NextCure, Inc. (NASDAQ:NXTC) posted its earnings results on Thursday, August, 7th. The company reported ($11.29) EPS for the quarter, missing analysts' consensus estimates of ($4.62) by $6.67.

NextCure's stock reverse split on the morning of Monday, July 14th 2025.The 1-12 reverse split was announced on Friday, June 20th 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

NextCure (NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure's top institutional shareholders include Cable Car Capital LP (28.29%), Geode Capital Management LLC (8.57%) and Pfizer Inc (5.88%).
View institutional ownership trends
.

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
8/07/2025
Today
8/30/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NXTC
CIK
1661059
Fax
N/A
Employees
90
Year Founded
2015

Price Target and Rating

High Price Target
$36.00
Low Price Target
$15.00
Potential Upside/Downside
+407.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($25.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.62%
Return on Assets
-85.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.71
Quick Ratio
3.71

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.82 per share
Price / Book
0.43

Miscellaneous

Outstanding Shares
2,680,000
Free Float
2,197,000
Market Cap
$13.48 million
Optionable
Optionable
Beta
1.25

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:NXTC) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners